| 0 (0%) | 10-15 12:14 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.39 | 1-year : | 6.89 |
| Resists | First : | 5.47 | Second : | 5.9 |
| Pivot price | 5.36  |
|||
| Supports | First : | 4.78 | Second : | 3.98 |
| MAs | MA(5) : | 5.08 |
MA(20) : | 5.38 |
| MA(100) : | 4.39 |
MA(250) : | 5.22 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 31.2 |
D(3) : | 23.1 |
| RSI | RSI(14): 49.4 |
|||
| 52-week | High : | 7.63 | Low : | 3.38 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MNKD ] has closed above bottom band by 33.7%. Bollinger Bands are 3.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.16 - 5.19 | 5.19 - 5.22 |
| Low: | 4.93 - 4.97 | 4.97 - 5 |
| Close: | 5.04 - 5.1 | 5.1 - 5.15 |
Wed, 15 Oct 2025
How to escape a deep drawdown in MNKD - Day Trade & Fast Momentum Entry Tips - newser.com
Wed, 15 Oct 2025
What risks investors should watch in MNKD stock - Quarterly Trade Review & High Accuracy Trade Alerts - newser.com
Wed, 15 Oct 2025
Is it too late to sell MNKD - Insider Buying & Real-Time Volume Analysis Alerts - newser.com
Wed, 15 Oct 2025
How MNKD stock responds to policy changes - Buy Signal & Expert Curated Trade Ideas - newser.com
Tue, 14 Oct 2025
MannKind (MNKD) Is Down 9.9% After FDA Reviews Afrezza for Pediatric Use Will Growth Prospects Shift? - simplywall.st
Mon, 13 Oct 2025
FDA accepts application for MannKind inhaled insulin in kids - Drug Delivery Business
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 307 (M) |
| Shares Float | 301 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 55.6 (%) |
| Shares Short | 18,310 (K) |
| Shares Short P.Month | 15,890 (K) |
| EPS | 0.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.19 |
| Profit Margin | 10.8 % |
| Operating Margin | 13.9 % |
| Return on Assets (ttm) | 10.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 5.6 % |
| Gross Profit (p.s.) | 0.73 |
| Sales Per Share | 0.98 |
| EBITDA (p.s.) | 0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 35 (M) |
| Levered Free Cash Flow | 29 (M) |
| PE Ratio | 47.36 |
| PEG Ratio | 0 |
| Price to Book value | -28.95 |
| Price to Sales | 5.29 |
| Price to Cash Flow | 46.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|